Literature DB >> 18549850

Emerging cardiovascular risk factors that account for a significant portion of attributable mortality risk in chronic kidney disease.

Mehdi H Shishehbor1, Leonardo P J Oliveira, Michael S Lauer, Dennis L Sprecher, Kathy Wolski, Leslie Cho, Byron J Hoogwerf, Stanley L Hazen.   

Abstract

Chronic kidney disease (CKD) increases cardiovascular risk and mortality. However, traditional cardiovascular risk factors do not adequately account for the substantial increase in mortality observed in CKD. The aim of this study was to examine the relative contributions of novel cardiovascular risk factors to the risk between CKD and mortality. The study population included 4,680 consecutive new patients from a tertiary care preventive cardiology program from 1996 to 2005. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease (MDRD) method. Baseline levels of traditional (low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, hypertension, triglycerides, total cholesterol, and fasting glucose) and emerging (apolipoproteins A-I and B, lipoprotein[a], fibrinogen, homocysteine, and high-sensitivity C-reactive protein) risk factors were examined. All-cause mortality was obtained from the Social Security Death Index. There were 278 deaths over a median follow-up period of 22 months. CKD (estimated glomerular filtration rate <or=60 ml/min/1.73 m(2)) was strongly associated with mortality after adjusting for traditional cardiovascular risk factors (hazard ratio 2.31, 95% confidence interval 1.77 to 3.11, p<0.001) and with the addition of propensity score (hazard ratio 2.33, 95% confidence interval 1.75 to 3.10, p<0.001). Of all the traditional and emerging risk factors monitored, only the addition of homocysteine and fibrinogen significantly attenuated the association between CKD and mortality (adjusted hazard ratio 1.73, 95% confidence interval 1.23 to 2.34, p<0.001), explaining 38% of the attributable mortality risk from CKD. A significant interaction (p=0.004) between homocysteine and estimated glomerular filtration rate was observed whereby the annual mortality rate in subjects with CKD with homocysteine <10 micromol/L (the bottom tertile) was similar to those with normal renal function (1% per year), whereas homocysteine levels >or=12.5 micromol/L (the top tertile) were associated with a sevenfold greater mortality risk. In conclusion, homocysteine and fibrinogen levels explain nearly 40% of the attributable mortality risk from CKD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18549850      PMCID: PMC3354958          DOI: 10.1016/j.amjcard.2008.02.060

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  27 in total

1.  Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function.

Authors:  Nicole M Isbel; Brian Haluska; David W Johnson; Elaine Beller; Carmel Hawley; Thomas H Marwick
Journal:  Am Heart J       Date:  2006-03       Impact factor: 4.749

2.  Homocysteine trials--clear outcomes for complex reasons.

Authors:  Joseph Loscalzo
Journal:  N Engl J Med       Date:  2006-03-12       Impact factor: 91.245

3.  Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients.

Authors:  Béatrice Descamps-Latscha; Véronique Witko-Sarsat; Thao Nguyen-Khoa; Anh Thu Nguyen; Valérie Gausson; Nadya Mothu; Gérard M London; Paul Jungers
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

Review 4.  Dyslipidemias in patients who have chronic kidney disease.

Authors:  Kambiz Farbakhsh; Bertram L Kasiske
Journal:  Med Clin North Am       Date:  2005-05       Impact factor: 5.456

Review 5.  Amino Acid and protein kinetics in renal failure: an integrated approach.

Authors:  Dominic S C Raj; Adeniyi Oladipo; Victoria S Lim
Journal:  Semin Nephrol       Date:  2006-03       Impact factor: 5.299

6.  Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.

Authors:  Sophia Zoungas; Barry P McGrath; Pauline Branley; Peter G Kerr; Christine Muske; Rory Wolfe; Robert C Atkins; Kathy Nicholls; Margaret Fraenkel; Brian G Hutchison; Robert Walker; John J McNeil
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

7.  Association of socioeconomic status with functional capacity, heart rate recovery, and all-cause mortality.

Authors:  Mehdi H Shishehbor; David Litaker; Claire E Pothier; Michael S Lauer
Journal:  JAMA       Date:  2006-02-15       Impact factor: 56.272

Review 8.  Overview of hemostatic factors involved in atherosclerotic cardiovascular disease.

Authors:  William B Kannel
Journal:  Lipids       Date:  2005-12       Impact factor: 1.880

9.  Folate therapy and in-stent restenosis after coronary stenting.

Authors:  Helmut Lange; Harry Suryapranata; Giuseppe De Luca; Caspar Börner; Joep Dille; Klaus Kallmayer; M Noor Pasalary; Eberhard Scherer; Jan-Henk E Dambrink
Journal:  N Engl J Med       Date:  2004-06-24       Impact factor: 91.245

10.  Glycoxidation and inflammation in renal failure patients.

Authors:  Melpomeni Peppa; Jaime Uribarri; Weijing Cai; Min Lu; Helen Vlassara
Journal:  Am J Kidney Dis       Date:  2004-04       Impact factor: 8.860

View more
  10 in total

1.  Endothelial progenitor cell dysfunction in patients with progressive chronic kidney disease.

Authors:  Guido Krenning; Patricia Y W Dankers; Johannes W Drouven; Femke Waanders; Casper F M Franssen; Marja J A van Luyn; Martin C Harmsen; Eliane R Popa
Journal:  Am J Physiol Renal Physiol       Date:  2009-04-01

2.  A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.

Authors:  Antonio Vukusich; Sonia Kunstmann; Cristian Varela; Daniela Gainza; Sebastian Bravo; Daniela Sepulveda; Gabriel Cavada; Luis Michea; Elisa T Marusic
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

3.  Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).

Authors:  Maple M Fung; Rany M Salem; Michael S Lipkowitz; Vibha Bhatnagar; Braj Pandey; Nicholas J Schork; Daniel T O'Connor
Journal:  Nephrol Dial Transplant       Date:  2011-05-25       Impact factor: 5.992

4.  Functional NMDA receptors with atypical properties are expressed in podocytes.

Authors:  Marc Anderson; Jae Mi Suh; Eun Young Kim; Stuart E Dryer
Journal:  Am J Physiol Cell Physiol       Date:  2010-08-25       Impact factor: 4.249

Review 5.  Baroreflex dysfunction in chronic kidney disease.

Authors:  Manpreet Kaur; Dinu S Chandran; Ashok Kumar Jaryal; Dipankar Bhowmik; Sanjay Kumar Agarwal; Kishore Kumar Deepak
Journal:  World J Nephrol       Date:  2016-01-06

Review 6.  Why do young people with chronic kidney disease die early?

Authors:  Shankar Kumar; Richard Bogle; Debasish Banerjee
Journal:  World J Nephrol       Date:  2014-11-06

7.  Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Authors:  Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2017-01-05       Impact factor: 10.121

8.  Residual Associations of Inflammatory Markers with eGFR after Accounting for Measured GFR in a Community-Based Cohort without CKD.

Authors:  Jørgen Schei; Vidar T N Stefansson; Ulla Dorte Mathisen; Bjørn O Eriksen; Marit D Solbu; Trond G Jenssen; Toralf Melsom
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-14       Impact factor: 8.237

9.  Adipose tissue-derived mesenchymal stromal cells for treating chronic kidney disease: A pilot study assessing safety and clinical feasibility.

Authors:  Sandra Villanueva; Fernando González; Eduardo Lorca; Andrés Tapia; Valentina G López; Rocío Strodthoff; Francisca Fajre; Juan E Carreño; Ricardo Valjalo; César Vergara; Manuel Lecanda; Jorge Bartolucci; Fernando E Figueroa; Maroun Khoury
Journal:  Kidney Res Clin Pract       Date:  2019-06-30

10.  Top Three Pharmacogenomics and Personalized Medicine Applications at the Nexus of Renal Pathophysiology and Cardiovascular Medicine.

Authors:  Murielle Bochud; Michel Burnier; Idris Guessous
Journal:  Curr Pharmacogenomics Person Med       Date:  2011-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.